

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

March 3, 2008
Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

001-32188
(Commission File Number)

59-3410522
(IRS Employer
Identification No.)

13700 Progress Boulevard
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities.

On February 29, 2008, Oragenics, Inc. (the "Company") announced that 3,386,364 warrants to purchase common stock previously issued by the Company were exercised by twelve warrant holders, resulting in aggregate proceeds to the Company of \$1,490,000. As previously reported by the Company on Form 8-K, the private placement offering and sale of the warrants was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933.

Item 5.02 Departure of Principal Officer; Appointment of Principal Officer

On February 12, 2008, the Board appointed Mr. Stanley Stein, also a member of the Board, as interim Chief Executive Officer and President. The Company has agreed to a compensation arrangement with Mr. Stein and the material terms include an annual salary of \$175,000. The expected tenure of his employment is until a permanent CEO is successfully recruited and retained.

There have been no changes with regards to other employees or the scientific and development team which will continue to work under Dr. Jeffrey Hillman's direction.

Item 9.01 Financial Information and Exhibits.**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated March 3, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 4, 2008

ORAGENICS, INC.
(Registrant)

BY: /s/ Stanley B. Stein

Stanley B. Stein

Interim President and Chief Executive Officer

Oragenics, Inc. Announces the Early Exercise of Warrants**FOR IMMEDIATE RELEASE**

ALACHUA, FL (March 3, 2008) – Oragenics, Inc. (AMEX:ONI), a biotechnology company focused primarily on infectious diseases, announced today that a total of 3,386,364 warrants issued to investors who participated in the August 2007 investment round in Oragenics have been exercised early at a price of \$0.44. This early exercise resulted in aggregate proceeds to the Company of \$1.49 million. The Company plans to use the proceeds of this warrant exercise to support its lead product development programs.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Dotti Delfino, 386-418-4018 X232
www.oragenics.com

###